Not Yet RecruitingNot Applicable

Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE)

France300 participantsStarted 2022-10-20

Plain-language summary

This study aims to identify novel inflammatory biomarkers in AC, whether in circulating blood, in situ or as imaging biomarkers to better understand the pathophysiology of the disease and then to determine contribution to the clinical management of patients.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patient (age ≥ 18 years old)
✓. Patient with a probable or confirmed diagnosis of cardiomyopathy according to the diagnostic criteria of the international task force
✓. Patient carrying a pathogenic mutation responsible for cardiomyopathy
✓. Patient informed individually of the research

Exclusion criteria

✕. Patients under curatorship/guardianship
✕. Pregnant women
✕. Patients who expressed their opposition to participate in the study

What they're measuring

Measure the correlation between the autoimmunity, inflammatory, and immunological profiles through biomarkers found in blood samples, myocardial biopsies, mass imaging cytometry, and cardiac imaging in patients with Arrhythmogenic Cardiomyopathy (AC)

Timeframe: 10 years

Trial details

NCT IDNCT05569356

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2032-10-20

Contact for this trial

Estelle GANDJBAKHCH, Dr

+33 1 42 16 30 55 estelle.gandjbakhch@aphp.fr

View on ClinicalTrials.gov More Arrhythmogenic Cardiomyopathy trials